Open Access and Peer-reviewed
Home Journal Issues Guide for Authors Editorial Board Aims & Scope About Journal News & Announcements


Original Research 
RMJ. 2020; 45(2): 282-286


Comparison of Atorvastatin and 0.1% Betamethasone Valerate in Psoriatic patients

Farah Jawed, Fatima Rizvi, Arfa Azhar, Jamal Ara, Zareen Naz, Jawed Iqbal.

Abstract
Objective: To compare effects of Atorvastatin (40mg/80mg) and 0.1% Betamethasone Valerate on progress of psoriasis with cardiovascular complications.
Methodology: This study was comparative interventional randomized clinical trial conducted in Pharmacology Department of Basic Medical Sciences Institute, Jinnah Postgraduate Medical Center (JPMC), with the collaboration of Dermatology department of JPMC, Karachi. The study period was from June 2013 to June 2016. A total of 225 patients were divided into group A, B and C. Post treatment effects of drugs were evaluated by different parameters (Psoriasis Area and Severity Index (PASI), High Sensitivity C-Reactive Protein (hsCRP), Lipid profile, Liver Function Test (LFT) Creatine Phosphokinase (CPK)). The quality of life was evaluated in those patients by Dermatological Life Quality Index(DLQI).
Results: The mean percentage change of PASI and hsCRP showed highly significant changes at twelve and twenty weeks. Before and after the treatment mean Lipid profile and DLQI also showed significant changed. LFT and adverse event had non-significant change at the end of treatment.
Conclusion: Atorvastatin had remarkable results on psoriasis disease severity and cardiovascular complication were same as standard therapy 0.1% Betamethasone Valerate. When the combination of drugs was used, more significant results were seen as compared to single therapy.

Key words: Atorvastatin, 0.1% Betamethasone Valerate, Psoriasis Severity and Cardiovascular complication.


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Farah Jawed
Articles by Fatima Rizvi
Articles by Arfa Azhar
Articles by Jamal Ara
Articles by Zareen Naz
Articles by Jawed Iqbal
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Jawed F, Rizvi F, Azhar A, Ara J, Naz Z, Iqbal J. Comparison of Atorvastatin and 0.1% Betamethasone Valerate in Psoriatic patients. RMJ. 2020; 45(2): 282-286.


Web Style

Jawed F, Rizvi F, Azhar A, Ara J, Naz Z, Iqbal J. Comparison of Atorvastatin and 0.1% Betamethasone Valerate in Psoriatic patients. http://www.rmj.org.pk/?mno=83520 [Access: May 10, 2020].


AMA (American Medical Association) Style

Jawed F, Rizvi F, Azhar A, Ara J, Naz Z, Iqbal J. Comparison of Atorvastatin and 0.1% Betamethasone Valerate in Psoriatic patients. RMJ. 2020; 45(2): 282-286.



Vancouver/ICMJE Style

Jawed F, Rizvi F, Azhar A, Ara J, Naz Z, Iqbal J. Comparison of Atorvastatin and 0.1% Betamethasone Valerate in Psoriatic patients. RMJ. (2020), [cited May 10, 2020]; 45(2): 282-286.



Harvard Style

Jawed, F., Rizvi, . F., Azhar, . A., Ara, . J., Naz, . Z. & Iqbal, . J. (2020) Comparison of Atorvastatin and 0.1% Betamethasone Valerate in Psoriatic patients. RMJ, 45 (2), 282-286.



Turabian Style

Jawed, Farah, Fatima Rizvi, Arfa Azhar, Jamal Ara, Zareen Naz, and Jawed Iqbal. 2020. Comparison of Atorvastatin and 0.1% Betamethasone Valerate in Psoriatic patients. Rawal Medical Journal, 45 (2), 282-286.



Chicago Style

Jawed, Farah, Fatima Rizvi, Arfa Azhar, Jamal Ara, Zareen Naz, and Jawed Iqbal. "Comparison of Atorvastatin and 0.1% Betamethasone Valerate in Psoriatic patients." Rawal Medical Journal 45 (2020), 282-286.



MLA (The Modern Language Association) Style

Jawed, Farah, Fatima Rizvi, Arfa Azhar, Jamal Ara, Zareen Naz, and Jawed Iqbal. "Comparison of Atorvastatin and 0.1% Betamethasone Valerate in Psoriatic patients." Rawal Medical Journal 45.2 (2020), 282-286. Print.



APA (American Psychological Association) Style

Jawed, F., Rizvi, . F., Azhar, . A., Ara, . J., Naz, . Z. & Iqbal, . J. (2020) Comparison of Atorvastatin and 0.1% Betamethasone Valerate in Psoriatic patients. Rawal Medical Journal, 45 (2), 282-286.








AUTHOR LOGIN

REVIEWER LOGIN

Indexed
&
Abstracted


Indexed in WHO Index Medicus IMEMR, Emromedex, Pakmedinet, ExtraMED and Scopus, Web of Science

  Approved by the Higher Education Commission of Pakistan and Pakistan Medical and Dental Council


ABOUT JOURNAL
POLICIES
STATEMENTS

This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author. This is in accordance with the Budapest Open Access Initiative (BOAI) definition of open access.

The articles in Rawal Medical Journal are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc-sa/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.